Diabetes Drug
GLP-1 agonists have transformed diabetes care. What's next?
A (Endocrinologist): The dual agonists (tirzepatide) and triple agonists (retatrutide) are even more potent—higher A1c reduction and 20-25% weight loss. But side effects (nausea, gastroparesis) are dose-limiting.
B (Pharmacist): The shortage crisis is real. Off-label prescribing for weight loss to the "worried well" has created scarcity for diabetic patients who need it for glucose control. We need tiered access or dedicated manufacturing lines.
C (Payer/Insurer): At $1,000+ per month, these drugs will bankrupt Medicare. We're requiring step therapy (metformin, then sulfonylureas, then GLP-1). Drug companies need to compete on price.
D (Patient): I suffered on metformin for 10 years with diarrhea. Ozempic gave me my life back—A1c from 9 to 6, lost 40 lbs. Stop calling me "off-label" and start covering it.